The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients

Full Band Spectra Analysis of Gait Acceleration Signals for Peripheral Arterial Disease Patients

Peripheral arterial disease (PAD) is an artherosclerotic occlusive disorder of distal arteries, which can give rise to the intermittent claudication (IC) phenomenon, i.e., limb pain and necessity to stop. PAD patients with IC have altered their gait, increasing the fall risk. Several gait analysis works have studied acceleration signals (from sensors) to characterize the gait. One common technique is spectral analysis. However, this approach mainly uses dominant frequency (f_d ) to characterize gait patterns, and in a narrow spectral band, disregarding the full spectra information. We propose to use a full band spectral analysis (up to 15 Hz) and the fundamental frequency (f₀) in order to completely characterize gait for both control subjects and PAD patients. Acceleration gait signals were recorded using an acquisition equipment consisting of four wireless sensor nodes located at ankle and hip height on both sides. Subjects had to walk, free-fashion, up to 10 min. The analysis of the periodicity of the gait acceleration signals, showed that f₀ is statistically higher (p < 0.05) in control subjects (0.9743 ± 0.0716) than in PAD patients (0.8748 ± 0.0438). Moreover, the spectral envelope showed that, in controls, the power spectral density distribution is higher than in PAD patients, and that the power concentration is hither around the f_d . In conclusion, full spectra analysis allowed to better characterize gait in PAD patients than classical spectral analysis. It allowed to better discriminate PAD patients and control subjects, and it also showed promising results to assess severity of PAD.

Exercise training and peripheral arterial disease

Peripheral arterial disease (PAD) is a common vascular disease that reduces blood flow capacity to the legs of patients. PAD leads to exercise intolerance that can progress in severity to greatly limit mobility, and in advanced cases leads to frank ischemia with pain at rest. It is estimated that 12 to 15 million people in the United States are diagnosed with PAD, with a much larger population that is undiagnosed. The presence of PAD predicts a 50% to 1500% increase in morbidity and mortality, depending on severity. Treatment of patients with PAD is limited to modification of cardiovascular disease risk factors, pharmacological intervention, surgery, and exercise therapy. Extended exercise programs that involve walking approximately five times per week, at a significant intensity that requires frequent rest periods, are most significant. Preclinical studies and virtually all clinical trials demonstrate the benefits of exercise therapy, including improved walking tolerance, modified inflammatory/hemostatic markers, enhanced vasoresponsiveness, adaptations within the limb (angiogenesis, arteriogenesis, and mitochondrial synthesis) that enhance oxygen delivery and metabolic responses, potentially delayed progression of the disease, enhanced quality of life indices, and extended longevity. A synthesis is provided as to how these adaptations can develop in the context of our current state of knowledge and events known to be orchestrated by exercise. The benefits are so compelling that exercise prescription should be an essential option presented to patients with PAD in the absence of contraindications. Obviously, selecting for a lifestyle pattern that includes enhanced physical activity prior to the advance of PAD limitations is the most desirable and beneficial.